BRAF and neoplasm: The oppositely behaving acidic N-glycan types, especially large, sulfated/phosphorylated, and putative terminal HexNAc containing glycans, showed a clear dependence on tumor stage and BRAF mutation status and may thus be associated with MSI CRC progression according to BRAF mutation.